Collagen 1 translation inhibitors and methods of use thereof

Collagen 1 translation inhibitors target activated fibroblasts to treat fibrosis and associated conditions, providing a safe and effective solution for reducing fibrosis severity and progression.

WO2025245046A1 Publication Date: 2025-11-27ANIMA BIOTECH INC
1 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/030095
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-21
Filing Date
2025-05-20
Publication Date
2025-11-27

AI Technical Summary

Technical Problem

Current treatments for fibrosis, such as systemic sclerosis, pulmonary fibrosis, and liver cirrhosis, are either toxic or ineffective, and there is a need for safe and effective therapeutic modalities to reduce fibrosis and its complications like portal hypertension and cirrhosis.

Method used

Development of Collagen 1 translation inhibitors represented by specific chemical structures (formula I, II, and/or structures listed in Table 1) to target activated fibroblasts and collagen overproduction, thereby treating fibrotic diseases.

Benefits of technology

The Collagen 1 translation inhibitors effectively reduce fibrosis severity, inhibit its progression, and treat associated conditions like idiopathic pulmonary fibrosis, liver cirrhosis, and non-alcoholic steatohepatitis, with potential for safe long-term use.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).
Need to check novelty before this filing date? Find Prior Art